Wealth Enhancement Advisory Services’s Gain Therapeutics GANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.5K Hold
17,056
– – ﹤0.01% 4095
2026
Q2
$30.7K Buy
17,056
+1,500
+10% +$2.76K ﹤0.01% 3992
2026
Q1
$28.8K Hold
15,556
– – ﹤0.01% 3477
2025
Q4
$39.7K Hold
15,556
– – ﹤0.01% 3542
2025
Q3
$31.4K Buy
+15,556
New +$26.2K ﹤0.01% 3471

Other funds holding GANX

Wealth Enhancement Advisory Services's GANX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services held its Gain Therapeutics (GANX) position steady in Q3 2026 at 17,056 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4095.

Wealth Enhancement Advisory Services first reported a position in GANX in Q3 2025 and has held it in 5 quarters since. The position peaked at $39.7K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 17,056 shares of Gain Therapeutics worth $27.5K as of Q3 2026.
  • Wealth Enhancement Advisory Services left its Gain Therapeutics share count unchanged in Q3 2026.
  • Gain Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4095 holding.
  • Wealth Enhancement Advisory Services first reported a position in Gain Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's Gain Therapeutics position peaked at $39.7K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.